• Exchange: NASDAQ GM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

KaloBios Pharmaceuticals Inc

+ Add to Watchlist


1.5600 USD 0.0700 4.29%

As of 20:10:00 ET on 12/26/2014.

Snapshot for KaloBios Pharmaceuticals Inc (KBIO)

Open: 1.6200 Day's Range: 1.5000 - 1.7000 Volume: 653,368
Previous Close: 1.6300 52wk Range: 1.3600 - 5.6100 1-Yr Rtn: -63.29%

Stock Chart for KBIO

No chart data available.
  • KBIO:US 1.5600
  • 1D
  • 1M
  • 1Y
Interactive KBIO Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for KBIO

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -1.1700
Est. EPS (USD) (12/2014) -1.1650
Est. PEG Ratio -
Market Cap (M USD) 51.46
Shares Outstanding (M) 32.99
30 Day Average Volume 211,055
Price/Book (mrq) 1.5226
Price/Sale (ttm) 12,878.0667
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/13/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for KBIO

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for KBIO

KaloBios Pharmaceuticals, Inc. operates as a biopharmaceutical company. The Company develops monoclonal antibodies designed to improve the lives of seriously ill patients with difficult-to-treat diseases, focusing on respiratory diseases and cancer such as cystic fibrosis, asthma, pneumonia, and tumors. KaloBios serves patients throughout the United States.

David W PritchardPresident/CEOHerbert C Cross "Herb"Chief Financial Officer
Donald R Joseph "Don"Chief Legal OfficerNestor A MolfinoChief Medical Officer
More Company Profile & Key Executives for KBIO

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil